Fulcrum Therapeutics (FULC) Operating Margin (2020 - 2024)

Fulcrum Therapeutics (FULC) has 5 years of Operating Margin data on file, last reported at 65.61% in Q2 2024.

• On a quarterly basis, Operating Margin rose 316698.0% year-over-year to 65.61% in Q2 2024; TTM through Jun 2025 was 105.97%, a 6582.0% decrease from a year earlier, with the FY2024 full-year figure at 27.37%, up 391787.0% from the prior year.
• Operating Margin for Q2 2024 stood at 65.61%, up from 3213.78% in the prior quarter.
• Over the last five years, Operating Margin for FULC reached as high as 65.61% in Q2 2024 and fell as low as 9471.19% in Q1 2023.
• Historically, Operating Margin has averaged 2044.08% across 5 years, with a median of 1033.77% in 2020.
• Across the five-year window, Operating Margin sank 846818 bps in 2023 and jumped 316698 bps in 2024, its largest moves.
• Year by year, Operating Margin stood at 420.99% in 2020, then slipped by 11 bps to 465.78% in 2021, then sank by 777 bps to 4083.65% in 2022, then increased by 21 bps to 3213.78% in 2023, then soared by 102 bps to 65.61% in 2024.
• Per Business Quant data, the three most recent Operating Margin figures were 65.61% in Q2 2024, 3213.78% in Q4 2023, and 3615.28% in Q3 2023.